Last reviewed · How we verify

GSK Biologicals' meningococcal vaccine GSK134612

GlaxoSmithKline · Phase 3 active Biologic

GSK Biologicals' meningococcal vaccine GSK134612 is a Meningococcal vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive meningococcal disease.

GSK134612 is a meningococcal vaccine that stimulates the immune system to produce antibodies against multiple serogroups of Neisseria meningitidis.

GSK134612 is a meningococcal vaccine that stimulates the immune system to produce antibodies against multiple serogroups of Neisseria meningitidis. Used for Prevention of invasive meningococcal disease.

At a glance

Generic nameGSK Biologicals' meningococcal vaccine GSK134612
SponsorGlaxoSmithKline
Drug classMeningococcal vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains antigens from meningococcal serogroups designed to elicit both humoral and cellular immune responses. By priming the adaptive immune system against these bacterial pathogens, the vaccine provides protection against invasive meningococcal disease and meningitis caused by the targeted serogroups.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK Biologicals' meningococcal vaccine GSK134612

What is GSK Biologicals' meningococcal vaccine GSK134612?

GSK Biologicals' meningococcal vaccine GSK134612 is a Meningococcal vaccine drug developed by GlaxoSmithKline, indicated for Prevention of invasive meningococcal disease.

How does GSK Biologicals' meningococcal vaccine GSK134612 work?

GSK134612 is a meningococcal vaccine that stimulates the immune system to produce antibodies against multiple serogroups of Neisseria meningitidis.

What is GSK Biologicals' meningococcal vaccine GSK134612 used for?

GSK Biologicals' meningococcal vaccine GSK134612 is indicated for Prevention of invasive meningococcal disease.

Who makes GSK Biologicals' meningococcal vaccine GSK134612?

GSK Biologicals' meningococcal vaccine GSK134612 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is GSK Biologicals' meningococcal vaccine GSK134612 in?

GSK Biologicals' meningococcal vaccine GSK134612 belongs to the Meningococcal vaccine class. See all Meningococcal vaccine drugs at /class/meningococcal-vaccine.

What development phase is GSK Biologicals' meningococcal vaccine GSK134612 in?

GSK Biologicals' meningococcal vaccine GSK134612 is in Phase 3.

What are the side effects of GSK Biologicals' meningococcal vaccine GSK134612?

Common side effects of GSK Biologicals' meningococcal vaccine GSK134612 include Injection site pain or erythema, Fever, Myalgia, Fatigue.

Related